Clinical Criteria Pathways—Part 1
Covered when the individual meets at least one of the following pathways. Where a pathway contains an AND branch, all listed conditions apply.
ONE of the following clinical pathways
ANY of the following
I
Individual is under 19 years of age.
II
Diagnosis of ampullary adenocarcinoma.
Disease is deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H).
Use
First-line therapy for intestinal metastatic disease.
Treatment of disease progression when there has been no prior immunotherapy.
III
Diagnosis of anal carcinoma (NCCN 2A).
Use as a single agent or in combination with paclitaxel and carboplatin.
IV
Diagnosis of appendiceal adenocarcinoma (NCCN 2A).
Use as a single agent with no prior checkpoint-inhibitor treatment.
Disease has dMMR/MSI-H or a POLE/POLD1 mutation with an ultra-hypermutated phenotype (for example, TMB >50 mut/Mb).
V
Treatment of bone cancer (NCCN 2A).
Use as monotherapy or with sunitinib for dedifferentiated chondrosarcoma (NCT03277924).
No prior anti-PD-1 or anti-PD-L1 agent.
Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
VI
Diagnosis of cervical cancer (NCCN 2A).
Use as a single agent for second-line or subsequent therapy.
CPS ≥1 for local/regional recurrence, stage IVB disease, or recurrence with distant metastases.
VII
Diagnosis of chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) (NCCN 2A).
Use as a single agent or with ibrutinib.
Histologic (Richter) transformation to diffuse large B-cell lymphoma.
Colorectal and Uterine Cancers
Coverage for colorectal and uterine neoplasms requires the applicable diagnosis, treatment setting, biomarker status, and prior-therapy conditions below.
ONE of the following
VIII—Resectable colorectal cancer
Diagnosis of colorectal cancer (NCCN 2A).
Use as monotherapy for resectable disease as neoadjuvant or initial treatment, including clinical T4b disease or bulky nodal disease.
Tumor is dMMR/MSI-H or has a POLE/POLD1 mutation with an ultra-hypermutated phenotype (for example, TMB >50 mut/Mb).
No prior anti-PD-1 or anti-PD-L1 agent.
Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
Esophageal, Gastric, and Esophagogastric-Junction Cancers
Coverage is available for the following esophageal, gastric, and esophagogastric-junction cancer pathways.
ONE of the following
XI—Advanced ESCC, first line
Unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) (label, NCCN 1 or 2A).
Use with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment.
Current ECOG performance status 0–2.
No prior checkpoint-inhibitor therapy, or no tumor progression while receiving a checkpoint inhibitor.
Individual is not receiving therapy for an autoimmune disease or chronic condition requiring a systemic immunosuppressant.
Hepatocellular, Histiocytic, Sarcoma-Related, Melanoma, and Merkel Cell Indications
Coverage includes the following hepatocellular, histiocytic, sarcoma-related, gestational trophoblastic, mesothelioma, and melanoma pathways.
ONE of the following
XIX—Hepatocellular carcinoma
Advanced hepatocellular carcinoma (label, NCCN 2A).
Use as a single agent for subsequent therapy with no prior checkpoint-inhibitor treatment.
XX—Histiocytic neoplasms
Primary malignant histiocytic neoplasm (NCCN 2A).
Use as a single agent for first-line or subsequent therapy.
Head and Neck, Urothelial, Thyroid, Gynecologic, and Skin Cancers
Coverage includes the following head and neck, urothelial, thyroid, and selected gynecologic and skin-cancer pathways.
ONE of the following
XXXIV—Recurrent or metastatic SCCHN
Recurrent, unresectable, or metastatic squamous cell carcinoma of the head and neck (label, NCCN 1).
Regimen
Monotherapy after progression on or after platinum-containing chemotherapy.
Combination with cetuximab for first-line or subsequent therapy (NCCN 2A).
XXXV—Nasopharyngeal cancer
Selected Disease-Specific Criteria
Additional covered disease-specific pathways are listed below.
ONE of the following
XL—Vaginal cancer
Recurrent or metastatic vaginal cancer (NCCN 2A).
Use as a single agent for second-line or subsequent therapy.
PD-L1-positive tumor (CPS ≥1%) or HPV-related tumor.
XLI—Vulvar cancer
Advanced or recurrent metastatic vulvar cancer (NCCN 2A).
Opdivo Qvantig may be substituted for intravenous nivolumab where the applicable FDA label or NCCN recommendation supports nivolumab. The package insert states that Opdivo Qvantig is not indicated in combination with ipilimumab (Yervoy).
Opdivo Qvantig is not approved for use in combination with intravenous ipilimumab.
Indications that do not meet one of the listed clinical criteria, and all other indications, are not approved under this policy.
Combination treatment with intravenous ipilimumab is not an approved use of Opdivo Qvantig.
Approval requires that the individual satisfy the applicable diagnosis, treatment, biomarker, prior-therapy, performance-status, and exclusion criteria in a covered pathway. Uses outside those criteria are not approved.
Uses outside the specified covered cancer diagnoses and treatment pathways are not medically necessary or approved under this policy.